* Sensei Biotherapeutics Inc SNSE.OQ SNSE.O is expected
to report resultson May 7 (estimated) for the period ending
March 31 2024
*
* LSEG's mean analyst estimate for Sensei Biotherapeutics
Inc is
for a loss of 28 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sensei
Biotherapeutics Inc is $4.00, above its last closing price
of $1.65.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.31 -0.31 -0.30 Beat 2.5
Sep. 30 2023 -0.34 -0.34 -0.28 Beat 17.4
Jun. 30 2023 -0.33 -0.33 -0.31 Beat 6.2
Mar. 31 2023 -0.36 -0.36 -0.33 Beat 7.3
Dec. -0.39 -0.40 -0.40 Met 0
31 2022
Jan. 1 0001 -0.37 -0.37 -0.44 Missed -18.9
Jun. 30 2022 -0.39 -0.39 -0.34 Beat 13.9
Mar. 31 2022 -0.36 -0.35 -0.40 Missed -14.3
This summary was machine generated May 3 at 16:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)